Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis.

Craig L LeonardiKyoungah SeeRussel T BurgeZhuoer SunYing ZhangLotus MallbrisAlyssa GarreltsRichard Bruce Warren

Published in: Advances in therapy (2022)

Brodalumab and ixekizumab had the lowest NNTs for achieving PASI responses at early time points and were not significantly different than risankizumab and guselkumab after 48/52 weeks.

Keyphrases

systematic review
rheumatoid arthritis
meta analyses
early onset
drug induced
case control
gestational age
preterm birth